At ESMO 2014 Congress, Prof Charles Swanton (London Research Institute and UCL, UK) discusses TRAcking Cancer Evolution through therapy (TRACERx), which is a study that defines lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis.
ESMO 2014: The TRACERx study of lung cancer
20th March 2015
Oncology
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given